The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Trading at Rs 367.85, Biocon shows a positive move in today's early trading session, with the stock included in the Nifty Midcap 150 index.

ICICI Securities is bearish on Biocon has recommended sell rating on the stock with a target price of Rs 270 in its research report dated August 09, 2025.

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

Biocon shares fell nearly 4% on Friday after the company posted its first-quarter (Q1) results for FY26, showing revenue growth but a sharp drop in profit. The company’s revenue from operations rose ...

Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...

Biocon's consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026. The pharma company reported a ...